 | • レポートコード：GIR-23F3795 • 出版社/出版日：GlobalInfoResearch / 2023年2月 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Drugs for Metabolic Disorders Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界の代謝疾患治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 代謝疾患治療薬市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・糖代謝異常治療薬、脂質代謝異常治療薬、アミノ酸代謝異常治療薬、その他 アプリケーション別セグメントは次のように区分されます。 ・病院、薬局 世界の代謝疾患治療薬市場の主要なマーケットプレーヤーは以下のとおりです。 ・Merck、Novartis、Takeda Pharmaceutical、Astra Zeneca、Boehringer Ingelheim、KOWA、Kythera、Fuji yakuhin、LG Life Science、Metsubishi Tanabe Pharma 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - 代謝疾患治療薬の概要 - タイプ別分析（2017年vs2021年vs2028年）：糖代謝異常治療薬、脂質代謝異常治療薬、アミノ酸代謝異常治療薬、その他 - アプリケーション別分析（2017年vs2021年vs2028年）：病院、薬局 - 世界の代謝疾患治療薬市場規模・予測 - 世界の代謝疾患治療薬生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Merck、Novartis、Takeda Pharmaceutical、Astra Zeneca、Boehringer Ingelheim、KOWA、Kythera、Fuji yakuhin、LG Life Science、Metsubishi Tanabe Pharma ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：糖代謝異常治療薬、脂質代謝異常治療薬、アミノ酸代謝異常治療薬、その他 ・アプリケーション別分析2017年-2028年：病院、薬局 ・代謝疾患治療薬の北米市場分析 - 代謝疾患治療薬の北米市場：タイプ別市場規模2017年-2028年 - 代謝疾患治療薬の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・代謝疾患治療薬のヨーロッパ市場分析 - ：代謝疾患治療薬のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：代謝疾患治療薬のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・代謝疾患治療薬のアジア太平洋市場分析 - 代謝疾患治療薬のアジア太平洋市場：タイプ別市場規模2017年-2028年 - 代謝疾患治療薬のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・代謝疾患治療薬の南米市場分析 - 代謝疾患治療薬の南米市場：タイプ別市場規模2017年-2028年 - 代謝疾患治療薬の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・代謝疾患治療薬の中東・アフリカ市場分析 - 代謝疾患治療薬の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 代謝疾患治療薬の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Drugs for Metabolic Disorders market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Drugs for Metabolic Disorders market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Drugs for Metabolic Disorders global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Glycogen Metabolism Disease Drug segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Drugs for Metabolic Disorders include Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, and Boehringer Ingelheim, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Drugs for Metabolic Disorders market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Market segment by Application can be divided into
Hospital
Retail Pharmacy
The key market players for global Drugs for Metabolic Disorders market are listed below:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for Metabolic Disorders product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for Metabolic Disorders, with price, sales, revenue and global market share of Drugs for Metabolic Disorders from 2019 to 2022.
Chapter 3, the Drugs for Metabolic Disorders competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for Metabolic Disorders breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Drugs for Metabolic Disorders market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Drugs for Metabolic Disorders.
Chapter 13, 14, and 15, to describe Drugs for Metabolic Disorders sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Drugs for Metabolic Disorders Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for Metabolic Disorders Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for Metabolic Disorders Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Global Drugs for Metabolic Disorders Market Size & Forecast
1.4.1 Global Drugs for Metabolic Disorders Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Drugs for Metabolic Disorders Sales in Volume (2017-2028)
1.4.3 Global Drugs for Metabolic Disorders Price (2017-2028)
1.5 Global Drugs for Metabolic Disorders Production Capacity Analysis
1.5.1 Global Drugs for Metabolic Disorders Total Production Capacity (2017-2028)
1.5.2 Global Drugs for Metabolic Disorders Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Drugs for Metabolic Disorders Market Drivers
1.6.2 Drugs for Metabolic Disorders Market Restraints
1.6.3 Drugs for Metabolic Disorders Trends Analysis
2 Manufacturers Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Drugs for Metabolic Disorders Product and Services
2.1.4 Merck Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Drugs for Metabolic Disorders Product and Services
2.2.4 Novartis Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Takeda Pharmaceutical
2.3.1 Takeda Pharmaceutical Details
2.3.2 Takeda Pharmaceutical Major Business
2.3.3 Takeda Pharmaceutical Drugs for Metabolic Disorders Product and Services
2.3.4 Takeda Pharmaceutical Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Astra Zeneca
2.4.1 Astra Zeneca Details
2.4.2 Astra Zeneca Major Business
2.4.3 Astra Zeneca Drugs for Metabolic Disorders Product and Services
2.4.4 Astra Zeneca Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Boehringer Ingelheim
2.5.1 Boehringer Ingelheim Details
2.5.2 Boehringer Ingelheim Major Business
2.5.3 Boehringer Ingelheim Drugs for Metabolic Disorders Product and Services
2.5.4 Boehringer Ingelheim Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 KOWA
2.6.1 KOWA Details
2.6.2 KOWA Major Business
2.6.3 KOWA Drugs for Metabolic Disorders Product and Services
2.6.4 KOWA Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Kythera
2.7.1 Kythera Details
2.7.2 Kythera Major Business
2.7.3 Kythera Drugs for Metabolic Disorders Product and Services
2.7.4 Kythera Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Fuji yakuhin
2.8.1 Fuji yakuhin Details
2.8.2 Fuji yakuhin Major Business
2.8.3 Fuji yakuhin Drugs for Metabolic Disorders Product and Services
2.8.4 Fuji yakuhin Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 LG Life Science
2.9.1 LG Life Science Details
2.9.2 LG Life Science Major Business
2.9.3 LG Life Science Drugs for Metabolic Disorders Product and Services
2.9.4 LG Life Science Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Metsubishi Tanabe Pharma
2.10.1 Metsubishi Tanabe Pharma Details
2.10.2 Metsubishi Tanabe Pharma Major Business
2.10.3 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product and Services
2.10.4 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Drugs for Metabolic Disorders Breakdown Data by Manufacturer
3.1 Global Drugs for Metabolic Disorders Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Drugs for Metabolic Disorders Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Drugs for Metabolic Disorders
3.4 Market Concentration Rate
3.4.1 Top 3 Drugs for Metabolic Disorders Manufacturer Market Share in 2021
3.4.2 Top 6 Drugs for Metabolic Disorders Manufacturer Market Share in 2021
3.5 Global Drugs for Metabolic Disorders Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Drugs for Metabolic Disorders Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Drugs for Metabolic Disorders Market Size by Region
4.1.1 Global Drugs for Metabolic Disorders Sales in Volume by Region (2017-2028)
4.1.2 Global Drugs for Metabolic Disorders Revenue by Region (2017-2028)
4.2 North America Drugs for Metabolic Disorders Revenue (2017-2028)
4.3 Europe Drugs for Metabolic Disorders Revenue (2017-2028)
4.4 Asia-Pacific Drugs for Metabolic Disorders Revenue (2017-2028)
4.5 South America Drugs for Metabolic Disorders Revenue (2017-2028)
4.6 Middle East and Africa Drugs for Metabolic Disorders Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Drugs for Metabolic Disorders Sales in Volume by Type (2017-2028)
5.2 Global Drugs for Metabolic Disorders Revenue by Type (2017-2028)
5.3 Global Drugs for Metabolic Disorders Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Drugs for Metabolic Disorders Sales in Volume by Application (2017-2028)
6.2 Global Drugs for Metabolic Disorders Revenue by Application (2017-2028)
6.3 Global Drugs for Metabolic Disorders Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Drugs for Metabolic Disorders Sales by Type (2017-2028)
7.2 North America Drugs for Metabolic Disorders Sales by Application (2017-2028)
7.3 North America Drugs for Metabolic Disorders Market Size by Country
7.3.1 North America Drugs for Metabolic Disorders Sales in Volume by Country (2017-2028)
7.3.2 North America Drugs for Metabolic Disorders Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Drugs for Metabolic Disorders Sales by Type (2017-2028)
8.2 Europe Drugs for Metabolic Disorders Sales by Application (2017-2028)
8.3 Europe Drugs for Metabolic Disorders Market Size by Country
8.3.1 Europe Drugs for Metabolic Disorders Sales in Volume by Country (2017-2028)
8.3.2 Europe Drugs for Metabolic Disorders Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Drugs for Metabolic Disorders Sales by Type (2017-2028)
9.2 Asia-Pacific Drugs for Metabolic Disorders Sales by Application (2017-2028)
9.3 Asia-Pacific Drugs for Metabolic Disorders Market Size by Region
9.3.1 Asia-Pacific Drugs for Metabolic Disorders Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Drugs for Metabolic Disorders Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Drugs for Metabolic Disorders Sales by Type (2017-2028)
10.2 South America Drugs for Metabolic Disorders Sales by Application (2017-2028)
10.3 South America Drugs for Metabolic Disorders Market Size by Country
10.3.1 South America Drugs for Metabolic Disorders Sales in Volume by Country (2017-2028)
10.3.2 South America Drugs for Metabolic Disorders Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Drugs for Metabolic Disorders Sales by Type (2017-2028)
11.2 Middle East & Africa Drugs for Metabolic Disorders Sales by Application (2017-2028)
11.3 Middle East & Africa Drugs for Metabolic Disorders Market Size by Country
11.3.1 Middle East & Africa Drugs for Metabolic Disorders Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Drugs for Metabolic Disorders Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Drugs for Metabolic Disorders and Key Manufacturers
12.2 Manufacturing Costs Percentage of Drugs for Metabolic Disorders
12.3 Drugs for Metabolic Disorders Production Process
12.4 Drugs for Metabolic Disorders Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Drugs for Metabolic Disorders Typical Distributors
13.3 Drugs for Metabolic Disorders Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Drugs for Metabolic Disorders Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Drugs for Metabolic Disorders Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Merck Basic Information, Manufacturing Base and Competitors
Table 4. Merck Major Business
Table 5. Merck Drugs for Metabolic Disorders Product and Services
Table 6. Merck Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Novartis Basic Information, Manufacturing Base and Competitors
Table 8. Novartis Major Business
Table 9. Novartis Drugs for Metabolic Disorders Product and Services
Table 10. Novartis Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 12. Takeda Pharmaceutical Major Business
Table 13. Takeda Pharmaceutical Drugs for Metabolic Disorders Product and Services
Table 14. Takeda Pharmaceutical Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Astra Zeneca Basic Information, Manufacturing Base and Competitors
Table 16. Astra Zeneca Major Business
Table 17. Astra Zeneca Drugs for Metabolic Disorders Product and Services
Table 18. Astra Zeneca Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 20. Boehringer Ingelheim Major Business
Table 21. Boehringer Ingelheim Drugs for Metabolic Disorders Product and Services
Table 22. Boehringer Ingelheim Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. KOWA Basic Information, Manufacturing Base and Competitors
Table 24. KOWA Major Business
Table 25. KOWA Drugs for Metabolic Disorders Product and Services
Table 26. KOWA Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Kythera Basic Information, Manufacturing Base and Competitors
Table 28. Kythera Major Business
Table 29. Kythera Drugs for Metabolic Disorders Product and Services
Table 30. Kythera Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Fuji yakuhin Basic Information, Manufacturing Base and Competitors
Table 32. Fuji yakuhin Major Business
Table 33. Fuji yakuhin Drugs for Metabolic Disorders Product and Services
Table 34. Fuji yakuhin Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. LG Life Science Basic Information, Manufacturing Base and Competitors
Table 36. LG Life Science Major Business
Table 37. LG Life Science Drugs for Metabolic Disorders Product and Services
Table 38. LG Life Science Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Metsubishi Tanabe Pharma Basic Information, Manufacturing Base and Competitors
Table 40. Metsubishi Tanabe Pharma Major Business
Table 41. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product and Services
Table 42. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Global Drugs for Metabolic Disorders Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 44. Global Drugs for Metabolic Disorders Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 45. Market Position of Manufacturers in Drugs for Metabolic Disorders, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 46. Global Drugs for Metabolic Disorders Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Drugs for Metabolic Disorders Production Site of Key Manufacturer
Table 48. Drugs for Metabolic Disorders New Entrant and Capacity Expansion Plans
Table 49. Drugs for Metabolic Disorders Mergers & Acquisitions in the Past Five Years
Table 50. Global Drugs for Metabolic Disorders Sales by Region (2017-2022) & (K Units)
Table 51. Global Drugs for Metabolic Disorders Sales by Region (2023-2028) & (K Units)
Table 52. Global Drugs for Metabolic Disorders Revenue by Region (2017-2022) & (USD Million)
Table 53. Global Drugs for Metabolic Disorders Revenue by Region (2023-2028) & (USD Million)
Table 54. Global Drugs for Metabolic Disorders Sales by Type (2017-2022) & (K Units)
Table 55. Global Drugs for Metabolic Disorders Sales by Type (2023-2028) & (K Units)
Table 56. Global Drugs for Metabolic Disorders Revenue by Type (2017-2022) & (USD Million)
Table 57. Global Drugs for Metabolic Disorders Revenue by Type (2023-2028) & (USD Million)
Table 58. Global Drugs for Metabolic Disorders Price by Type (2017-2022) & (USD/Unit)
Table 59. Global Drugs for Metabolic Disorders Price by Type (2023-2028) & (USD/Unit)
Table 60. Global Drugs for Metabolic Disorders Sales by Application (2017-2022) & (K Units)
Table 61. Global Drugs for Metabolic Disorders Sales by Application (2023-2028) & (K Units)
Table 62. Global Drugs for Metabolic Disorders Revenue by Application (2017-2022) & (USD Million)
Table 63. Global Drugs for Metabolic Disorders Revenue by Application (2023-2028) & (USD Million)
Table 64. Global Drugs for Metabolic Disorders Price by Application (2017-2022) & (USD/Unit)
Table 65. Global Drugs for Metabolic Disorders Price by Application (2023-2028) & (USD/Unit)
Table 66. North America Drugs for Metabolic Disorders Sales by Country (2017-2022) & (K Units)
Table 67. North America Drugs for Metabolic Disorders Sales by Country (2023-2028) & (K Units)
Table 68. North America Drugs for Metabolic Disorders Revenue by Country (2017-2022) & (USD Million)
Table 69. North America Drugs for Metabolic Disorders Revenue by Country (2023-2028) & (USD Million)
Table 70. North America Drugs for Metabolic Disorders Sales by Type (2017-2022) & (K Units)
Table 71. North America Drugs for Metabolic Disorders Sales by Type (2023-2028) & (K Units)
Table 72. North America Drugs for Metabolic Disorders Sales by Application (2017-2022) & (K Units)
Table 73. North America Drugs for Metabolic Disorders Sales by Application (2023-2028) & (K Units)
Table 74. Europe Drugs for Metabolic Disorders Sales by Country (2017-2022) & (K Units)
Table 75. Europe Drugs for Metabolic Disorders Sales by Country (2023-2028) & (K Units)
Table 76. Europe Drugs for Metabolic Disorders Revenue by Country (2017-2022) & (USD Million)
Table 77. Europe Drugs for Metabolic Disorders Revenue by Country (2023-2028) & (USD Million)
Table 78. Europe Drugs for Metabolic Disorders Sales by Type (2017-2022) & (K Units)
Table 79. Europe Drugs for Metabolic Disorders Sales by Type (2023-2028) & (K Units)
Table 80. Europe Drugs for Metabolic Disorders Sales by Application (2017-2022) & (K Units)
Table 81. Europe Drugs for Metabolic Disorders Sales by Application (2023-2028) & (K Units)
Table 82. Asia-Pacific Drugs for Metabolic Disorders Sales by Region (2017-2022) & (K Units)
Table 83. Asia-Pacific Drugs for Metabolic Disorders Sales by Region (2023-2028) & (K Units)
Table 84. Asia-Pacific Drugs for Metabolic Disorders Revenue by Region (2017-2022) & (USD Million)
Table 85. Asia-Pacific Drugs for Metabolic Disorders Revenue by Region (2023-2028) & (USD Million)
Table 86. Asia-Pacific Drugs for Metabolic Disorders Sales by Type (2017-2022) & (K Units)
Table 87. Asia-Pacific Drugs for Metabolic Disorders Sales by Type (2023-2028) & (K Units)
Table 88. Asia-Pacific Drugs for Metabolic Disorders Sales by Application (2017-2022) & (K Units)
Table 89. Asia-Pacific Drugs for Metabolic Disorders Sales by Application (2023-2028) & (K Units)
Table 90. South America Drugs for Metabolic Disorders Sales by Country (2017-2022) & (K Units)
Table 91. South America Drugs for Metabolic Disorders Sales by Country (2023-2028) & (K Units)
Table 92. South America Drugs for Metabolic Disorders Revenue by Country (2017-2022) & (USD Million)
Table 93. South America Drugs for Metabolic Disorders Revenue by Country (2023-2028) & (USD Million)
Table 94. South America Drugs for Metabolic Disorders Sales by Type (2017-2022) & (K Units)
Table 95. South America Drugs for Metabolic Disorders Sales by Type (2023-2028) & (K Units)
Table 96. South America Drugs for Metabolic Disorders Sales by Application (2017-2022) & (K Units)
Table 97. South America Drugs for Metabolic Disorders Sales by Application (2023-2028) & (K Units)
Table 98. Middle East & Africa Drugs for Metabolic Disorders Sales by Region (2017-2022) & (K Units)
Table 99. Middle East & Africa Drugs for Metabolic Disorders Sales by Region (2023-2028) & (K Units)
Table 100. Middle East & Africa Drugs for Metabolic Disorders Revenue by Region (2017-2022) & (USD Million)
Table 101. Middle East & Africa Drugs for Metabolic Disorders Revenue by Region (2023-2028) & (USD Million)
Table 102. Middle East & Africa Drugs for Metabolic Disorders Sales by Type (2017-2022) & (K Units)
Table 103. Middle East & Africa Drugs for Metabolic Disorders Sales by Type (2023-2028) & (K Units)
Table 104. Middle East & Africa Drugs for Metabolic Disorders Sales by Application (2017-2022) & (K Units)
Table 105. Middle East & Africa Drugs for Metabolic Disorders Sales by Application (2023-2028) & (K Units)
Table 106. Drugs for Metabolic Disorders Raw Material
Table 107. Key Manufacturers of Drugs for Metabolic Disorders Raw Materials
Table 108. Direct Channel Pros & Cons
Table 109. Indirect Channel Pros & Cons
Table 110. Drugs for Metabolic Disorders Typical Distributors
Table 111. Drugs for Metabolic Disorders Typical Customers
List of Figures
Figure 1. Drugs for Metabolic Disorders Picture
Figure 2. Global Drugs for Metabolic Disorders Revenue Market Share by Type in 2021
Figure 3. Glycogen Metabolism Disease Drug
Figure 4. Lipid Metabolism Disease Drug
Figure 5. Amino Acid Metabolism Drug
Figure 6. Other
Figure 7. Global Drugs for Metabolic Disorders Revenue Market Share by Application in 2021
Figure 8. Hospital
Figure 9. Retail Pharmacy
Figure 10. Global Drugs for Metabolic Disorders Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Drugs for Metabolic Disorders Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Drugs for Metabolic Disorders Sales (2017-2028) & (K Units)
Figure 13. Global Drugs for Metabolic Disorders Price (2017-2028) & (USD/Unit)
Figure 14. Global Drugs for Metabolic Disorders Production Capacity (2017-2028) & (K Units)
Figure 15. Global Drugs for Metabolic Disorders Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Drugs for Metabolic Disorders Market Drivers
Figure 17. Drugs for Metabolic Disorders Market Restraints
Figure 18. Drugs for Metabolic Disorders Market Trends
Figure 19. Global Drugs for Metabolic Disorders Sales Market Share by Manufacturer in 2021
Figure 20. Global Drugs for Metabolic Disorders Revenue Market Share by Manufacturer in 2021
Figure 21. Drugs for Metabolic Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Drugs for Metabolic Disorders Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Drugs for Metabolic Disorders Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Drugs for Metabolic Disorders Sales Market Share by Region (2017-2028)
Figure 25. Global Drugs for Metabolic Disorders Revenue Market Share by Region (2017-2028)
Figure 26. North America Drugs for Metabolic Disorders Revenue (2017-2028) & (USD Million)
Figure 27. Europe Drugs for Metabolic Disorders Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Drugs for Metabolic Disorders Revenue (2017-2028) & (USD Million)
Figure 29. South America Drugs for Metabolic Disorders Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Drugs for Metabolic Disorders Revenue (2017-2028) & (USD Million)
Figure 31. Global Drugs for Metabolic Disorders Sales Market Share by Type (2017-2028)
Figure 32. Global Drugs for Metabolic Disorders Revenue Market Share by Type (2017-2028)
Figure 33. Global Drugs for Metabolic Disorders Price by Type (2017-2028) & (USD/Unit)
Figure 34. Global Drugs for Metabolic Disorders Sales Market Share by Application (2017-2028)
Figure 35. Global Drugs for Metabolic Disorders Revenue Market Share by Application (2017-2028)
Figure 36. Global Drugs for Metabolic Disorders Price by Application (2017-2028) & (USD/Unit)
Figure 37. North America Drugs for Metabolic Disorders Sales Market Share by Type (2017-2028)
Figure 38. North America Drugs for Metabolic Disorders Sales Market Share by Application (2017-2028)
Figure 39. North America Drugs for Metabolic Disorders Sales Market Share by Country (2017-2028)
Figure 40. North America Drugs for Metabolic Disorders Revenue Market Share by Country (2017-2028)
Figure 41. United States Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Drugs for Metabolic Disorders Sales Market Share by Type (2017-2028)
Figure 45. Europe Drugs for Metabolic Disorders Sales Market Share by Application (2017-2028)
Figure 46. Europe Drugs for Metabolic Disorders Sales Market Share by Country (2017-2028)
Figure 47. Europe Drugs for Metabolic Disorders Revenue Market Share by Country (2017-2028)
Figure 48. Germany Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Drugs for Metabolic Disorders Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Drugs for Metabolic Disorders Revenue Market Share by Region (2017-2028)
Figure 57. China Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Drugs for Metabolic Disorders Sales Market Share by Type (2017-2028)
Figure 64. South America Drugs for Metabolic Disorders Sales Market Share by Application (2017-2028)
Figure 65. South America Drugs for Metabolic Disorders Sales Market Share by Country (2017-2028)
Figure 66. South America Drugs for Metabolic Disorders Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Drugs for Metabolic Disorders Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Drugs for Metabolic Disorders Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Drugs for Metabolic Disorders Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Drugs for Metabolic Disorders Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Drugs for Metabolic Disorders Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Drugs for Metabolic Disorders in 2021
Figure 78. Manufacturing Process Analysis of Drugs for Metabolic Disorders
Figure 79. Drugs for Metabolic Disorders Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source